Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an announcement.
Roquefort Therapeutics PLC has announced an extension of the maturity date for its convertible loan notes to December 31, 2025. This extension provides the company with additional time to focus on completing transactions with Lyramid and Oncogeni, as well as exploring other potential mergers and acquisitions in the life sciences sector.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing first-in-class medicines in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes five novel patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 2,864,378
Technical Sentiment Signal: Sell
Current Market Cap: £2.56M
For an in-depth examination of ROQ stock, go to TipRanks’ Stock Analysis page.